Multi-state outcome analysis of treatments (MOAT): Application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder

Molecular Psychiatry

Volumn 21, Issue 2, 2016, Pages 237-242

  Bowden, C L ^a   Mintz, J ^a   Tohen, M ^b  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; LITHIUM; PLACEBO; NEUROLEPTIC AGENT; TRANQUILIZER; TRIAZINE DERIVATIVE;

ARTICLE; BIPOLAR DISORDER; DATA BASE; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON DEPRESSION RATING SCALE; HUMAN; LONGITUDINAL STUDY; MANIA; METHODOLOGY; MIXED MANIA AND DEPRESSION; MULTI STATE OUTCOME ANALYSIS OF TREATMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; COMPARATIVE STUDY; DEPRESSIVE DISORDER; FEMALE; MALE; MIDDLE AGED;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; FEMALE; HUMANS; LITHIUM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZINES;

EID: 84955197995     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.21     Document Type: Article

References (27)

1. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-1276.
2. Gelber RD, Cole BF, Gelber S, Aron G. Comparing treatments using qualityadjusted survival: The Q-Twist method. Am Stat 1995; 49: 161-169.
3. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter DJ, Jones DR et al. Quality-of-life assessment: can we keep it simple? JSTOR 1992; 155: 40.
4. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990; 47: 1106-1111.
5. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA et al. The longterm natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
6. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024.
7. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
8. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441.
9. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN et al. The international society for bipolar disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11: 453-473.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
11. Endicott J, Spitzer RL. A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837-844.
12. Datta S. Estimating the mean life time using right censored data. Stat Methodol 2004; 2: 5.
13. Zhong M, Hess KR. Mean survival time from right censored data. Collect Biostat Res Arch 2009; 66: 1-5.
14. Efron B. The two sample problem with censored data. Berkeley Symp Math Stat Prob 1967; 4.
15. Cochran W. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
16. Lanza ST, DJ J, Huang L, Xu S, Collins LM. Software Proc LCA & Proc LTA users' guide (Version 1. 2. 7). 2011, University Park: The Methodology Center: Pennsylvania, USA.
17. Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Ketter TA, Calabrese JR et al. Lithium treatment-moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials 2009; 6: 637-648.
18. Baethge C, Schlattmann P. A survival analysis for recurrent events in psychiatric research. Bipolar Disord 2004; 6: 7.
19. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods, (2nd ed. ) SAGE Publications: University of Chicago, 2002.
20. Roussos P, Giakoumaki SG, Georgakopoulos A, Robakis NK, Bitsios P. The CACNA1C and ANK3 risk alleles impact on affective personality traits and startle reactivity but not on cognition or gating in healthy males. Bipolar Disord 2011; 13: 250-259.
21. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056-1058.
22. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K et al. Whole-genome association study of bipolar disorder. Mol Psychiatry 2008; 13: 558-569.
23. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488.
24. Gonzalez JM, Bowden CL, Katz MM, Thompson P, Singh V, Prihoda TJ et al. Development of the bipolar inventory of symptoms scale: concurrent validity, discriminant validity and retest reliability. Int J Methods Psychiatr Res 2008; 17: 198-209.
25. Thompson PM, Gonzalez JM, Singh V, Schoolfield JD, Katz MM, Bowden CL et al. Principal domains of behavioral psychopathology identified by the bipolar inventory of signs and symptoms scale (BISS). Psychiatry Res 2010; 175: 221-226.
26. Srivastava S, Ketter TA. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clinical Ther 2011; 33: B40-B48.
27. Singh V, Bowden CL, Gonzalez JM, Thompson P, Prihoda TJ, Katz MM et al. Discriminating primary clinical states in bipolar disorder with a comprehensive symptom scale. Acta Psychiatr Scand 2013; 127: 145-152.